Review
Nature Reviews Drug Discovery 5, 919-931 (November 2006) | doi:10.1038/nrd2136
The obesity pipeline: current strategies in the development of anti-obesity drugs
Dunstan Cooke1 & Steve Bloom1,2 About the authors
Abstract
This review provides a summary of currently available pharmaceutical therapies for the treatment of obesity, along with an overview of the pipeline of products currently in development, and the key mechanisms on which the major development candidates are based. In particular, the recent increase in understanding of the role of gut peptides in energy homeostasis is highlighted as a promising source of potential future obesity therapies.
- View At a Glance
Author affiliations
- Thiakis Limited, Imperial BioIncubator, Bessemer Building (RSM), Prince Consort Road, London SW7 2BP, UK.
- Department of Metabolic Medicine, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London W12 ONN, UK.
Correspondence to: Steve Bloom1,2 Email: s.bloom@imperial.ac.uk
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Triglycerides and toggling the tummyNature Genetics News and Views (01 May 2000)
Cellular energy sensor balances the scalesNature Medicine News and Views (01 Jul 2004)
RESEARCH
Perspective on the Central Control of AppetiteObesity Article Response
See all 32 matches for Research
